Lake Street Advisors Group LLC Purchases Shares of 10,480 Takeda Pharmaceutical Company Limited (NYSE:TAK)

Lake Street Advisors Group LLC purchased a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,480 shares of the company’s stock, valued at approximately $139,000.

A number of other institutional investors have also recently added to or reduced their stakes in TAK. Allspring Global Investments Holdings LLC grew its position in Takeda Pharmaceutical by 62.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 17,759 shares of the company’s stock valued at $253,000 after acquiring an additional 6,852 shares during the period. US Bancorp DE boosted its position in shares of Takeda Pharmaceutical by 11.9% in the third quarter. US Bancorp DE now owns 102,588 shares of the company’s stock worth $1,459,000 after buying an additional 10,925 shares during the period. Van ECK Associates Corp grew its stake in shares of Takeda Pharmaceutical by 6.6% in the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock valued at $30,149,000 after buying an additional 134,407 shares in the last quarter. BSW Wealth Partners grew its stake in shares of Takeda Pharmaceutical by 15.7% in the third quarter. BSW Wealth Partners now owns 22,090 shares of the company’s stock valued at $314,000 after buying an additional 2,992 shares in the last quarter. Finally, QRG Capital Management Inc. grew its stake in shares of Takeda Pharmaceutical by 4.5% in the third quarter. QRG Capital Management Inc. now owns 282,154 shares of the company’s stock valued at $4,012,000 after buying an additional 12,035 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

TAK stock opened at $14.40 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $15.08. The firm has a market cap of $45.82 billion, a P/E ratio of 36.00, a price-to-earnings-growth ratio of 0.24 and a beta of 0.51. The stock has a 50-day simple moving average of $13.41 and a 200-day simple moving average of $13.89.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, equities analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.